In Russia, the vaccine TRIVAID against measles, mumps, and rubella has been registered, with an experience of more than 300 million doses administered worldwide.

In Russia, the vaccine TRIVAID against measles, mumps, and rubella has been registered, with an experience of more than 300 million doses administered worldwide. The vaccine from PHARM AID, under the trade name TRIVAID, was registered in the Russian Federation on April 27, 2024, and is intended for active immunization of various age groups, including children starting at 12 months of age. The administration schedule includes both vaccination and revaccination. The vaccine induces the formation of specific antibodies against these viruses and stimulates the development of immunity to the respective diseases. The new drug expands the possibilities for the medical community in preventing serious infectious diseases that pose a threat of severe complications and fatalities. "The relevance of combating measles, mumps, and rubella in the Russian Federation remains an important task. The only way to prevent these infections is to achieve a high level of population coverage with vaccination (for example, ≥95% for measles), which will prevent the spread of the disease when imported from other regions. Our goal is to make this vaccine accessible to all age groups," emphasized Azamat Metov, CEO of PHARM AID.

About the company

The registration certificate holder is PHARM AID, a pharmaceutical company founded in 2017 to transfer technology for the production of innovative biotech products to Russia. TRIVAID is the second vaccine in the company's portfolio (PHARM AID is the largest supplier of rotavirus vaccine in Russia). PHARM AID is implementing a project to build a production site for the release of innovative immunobiological drugs for the prevention and treatment of various diseases in the "Vorsino" industrial park in the Kaluga region. We are developing international cooperation with leading global pharmaceutical companies, an example of which is the TRIVAID vaccine, produced by Serum Institute of India, one of the largest vaccine manufacturers in the world.